<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02828150</url>
  </required_header>
  <id_info>
    <org_study_id>2015013559</org_study_id>
    <nct_id>NCT02828150</nct_id>
  </id_info>
  <brief_title>Integrative Parenteral Nutrition in Cancer Patients</brief_title>
  <official_title>Integrative Parenteral Nutrition in Hospitalized, Malnourished, Hypophagic Cancer Patients With Contraindication to Enteral Nutrition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Policlinico S. Matteo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS Policlinico S. Matteo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although it is demonstrated that nutritional support can improve clinical outcomes, the
      literature shows that approximately 50% of cancer patients are not able to meet their
      estimated energy requirements. Recent clinical studies suggest that a supplementary support
      for parenteral nutrition (PN) could significantly help to improve the nutritional status of
      malnourished cancer patients.

      International guidelines recommend the use of PN in malnourished, hypophagic, non-surgical
      cancer patients if enteral nutrition is not feasible and in patients affected by severe
      iatrogenic gastrointestinal complications and in whom inadequate food intake is anticipated
      for more than 7 days. However, there are no studies on the effects of integrative PN in
      hospitalized, malnourished, hypophagic, non-surgical cancer patients.

      Recent studies have reported on the validity of bioelectrical impedance vector analysis in
      monitoring the body composition of patients receiving nutritional support. Particularly,
      phase angle proved to be a superior prognostic marker than other nutritional screening tools.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase angle</measure>
    <time_frame>7 days</time_frame>
    <description>Change in phase angle (a specific body composition parameter assessed by bioelectrical impedance vector analysis) after 7 days of nutritional support</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>body weight</measure>
    <time_frame>7 days</time_frame>
    <description>Change in body weight after 7 days of nutritional support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body mass index</measure>
    <time_frame>7 days</time_frame>
    <description>Change in body mass index after 7 days of nutritional support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Handgrip strength</measure>
    <time_frame>7 days</time_frame>
    <description>Changes in muscle strength after 7 days of nutritional support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by biochemistry</measure>
    <time_frame>7 days</time_frame>
    <description>Changes in biochemistry after 7 days of nutritional support</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">131</enrollment>
  <condition>Neoplasms</condition>
  <condition>Parenteral Nutrition</condition>
  <arm_group>
    <arm_group_label>Parenteral nutrition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a tailored nutritional support (parenteral nutrition) to cover estimated protein-calorie requirements</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Parenteral nutrition</intervention_name>
    <description>Patients will receive a tailored nutritional support (parenteral nutrition) to cover estimated protein-calorie requirements. Energy: resting energy expenditure [Harris-Benedict] multiplied by a factor of 1.5. Protein: 1.5 g/kg/day. In obese patients (BMI &gt;30 kg/m2) support will be calculated on ideal body weight (BMI=23 kg/m2)</description>
    <arm_group_label>Parenteral nutrition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of cancer (head-neck, lung, gastrointestinal, pancreas, biliary tract,
             haematology).

          -  Nutritional Risk Screening 2002 score ≥3.

          -  Expected duration of parenteral nutrition ≥7 days

          -  Availability to planned measurements

          -  Contraindication to enteral nutrition support

          -  Written informed consent

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Ongoing artificial nutrition before hospitalization

          -  Eastern Cooperative Oncology Group performance status &gt;2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Riccardo Caccialanza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS Policlinico San Matteo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Caccialanza R, Cereda E, Klersy C, Bonardi C, Cappello S, Quarleri L, Turri A, Montagna E, Iacona I, Valentino F, Pedrazzoli P. Phase angle and handgrip strength are sensitive early markers of energy intake in hypophagic, non-surgical patients at nutritional risk, with contraindications to enteral nutrition. Nutrients. 2015 Mar 11;7(3):1828-40. doi: 10.3390/nu7031828.</citation>
    <PMID>25768953</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2016</study_first_submitted>
  <study_first_submitted_qc>July 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2016</study_first_posted>
  <last_update_submitted>December 1, 2017</last_update_submitted>
  <last_update_submitted_qc>December 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Policlinico S. Matteo</investigator_affiliation>
    <investigator_full_name>Riccardo Caccialanza</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

